☆ 4.7 Article

Estetrol Is Safe and Well Tolerated during Treatment of Hospitalized Men and Women with Moderate COVID-19 in a Randomized, Double-Blind Study

JOURNAL OF CLINICAL MEDICINE (2023)

Related references

Note: Only part of the references are listed.

Article Geriatrics & Gerontology

Effect of menopausal hormone therapy on COVID-19 severe outcomes in women-A population-based study of the US National COVID Cohort Collaborative (N3C) data

Yilin Yoshida et al.

Summary: Using a U.S. national COVID-19 cohort and cross-sectional analysis, it was found that menopausal hormone therapy (MHT) use was associated with a lower risk of mortality and prolonged hospital stay among inpatient women. Estrogen-only and estrogen-plus-progestin therapies had a more prominent protective effect than progestin-only therapy.

MATURITAS (2023)

Add to Collection

Article Obstetrics & Gynecology

Impact of estetrol (E4) on hemostasis, metabolism and bone turnover in postmenopausal women

J. Douxfils et al.

Summary: This study found that estetrol (E4) has limited effects on hemostasis in postmenopausal women, but it may have beneficial effects on lipids, carbohydrate metabolism, and bone turnover.

CLIMACTERIC (2023)

Add to Collection

Review Infectious Diseases

Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials

Charan Thej Reddy Vegivinti et al.

Summary: This study reviewed current evidence from randomized clinical trials on the efficacy of antivirals for COVID-19 treatment. It found that antivirals were more effective when administered early in the disease course, but none demonstrated efficacy in reducing COVID-19 mortality. Larger randomized controlled trials are needed to establish efficacy conclusively.

BMC INFECTIOUS DISEASES (2022)

Add to Collection

Article Medicine, General & Internal

Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial

Karim Ali et al.

Summary: This Canadian study explores the effectiveness of remdesivir as a treatment for COVID-19. The results show that remdesivir has a modest but significant impact on important outcomes for patients and healthcare systems, such as the need for mechanical ventilation.

CANADIAN MEDICAL ASSOCIATION JOURNAL (2022)

Add to Collection

Article Infectious Diseases

Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial

Florence Ader et al.

Summary: A study conducted in COVID-19 patients admitted to hospital and requiring oxygen support found that remdesivir did not show significant clinical benefits compared to standard care alone.

LANCET INFECTIOUS DISEASES (2022)

Add to Collection

Article Pharmacology & Pharmacy

Profile of estetrol, a promising native estrogen for oral contraception and the relief of climacteric symptoms of menopause

Celine Gerard et al.

Summary: This narrative review discusses the pharmacological characteristics and mode of action of E4 as an oral contraceptive, as well as the results of clinical studies in contraception, menopause, and oncology. E4 has a distinct profile of ER alpha activation, which leads to its favorable safety and tolerability.

EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2022)

Add to Collection

Article Endocrinology & Metabolism

Low Thrombin Generation in Users of a Contraceptive Containing Estetrol and Drospirenone

Laure Morimont et al.

Summary: The study compared the impact of a new combined oral contraceptive containing 15 mg estetrol and 3 mg drospirenone with oral contraceptives containing ethinylestradiol (30 or 20 mcg) in combination with either 150 mcg levonorgestrel or 3 mg drospirenone on thrombin generation. The results showed that the estetrol/drospirenone combination had less impact on thrombin generation compared to ethinylestradiol-containing products, which increased the production of procoagulant factors and decreased the production of anticoagulant ones, creating a prothrombotic state.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2022)

Add to Collection

Article Medicine, General & Internal

Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses

Summary: This study presents the final results of the Solidarity trial and meta-analyses of mortality in relevant trials. The findings suggest that remdesivir does not have a significant effect on COVID-19 patients who are already on ventilators. However, it does have a small effect against death or progression to ventilation in other hospitalized patients.

LANCET (2022)

Add to Collection

Article Medicine, General & Internal

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

A. C. Kalil et al.

Summary: Combination treatment with baricitinib plus remdesivir was superior to remdesivir alone in reducing recovery time and accelerating improvement in clinical status among patients with Covid-19, notably among those receiving high-flow oxygen or noninvasive ventilation. The combination was associated with fewer serious adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia

Carlos Salama et al.

Summary: Among hospitalized patients with Covid-19 pneumonia not on mechanical ventilation, tocilizumab reduced the risk of progression to mechanical ventilation or death, but did not improve overall survival. There were no new safety concerns identified.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Critical Care Medicine

Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial

Ivan O. Rosas et al.

Summary: In patients with severe COVID-19 pneumonia, tocilizumab plus remdesivir did not reduce the time to hospital discharge or readiness for discharge compared to placebo plus remdesivir by day 28.

INTENSIVE CARE MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia

I. O. Rosas et al.

Summary: In this randomized trial involving hospitalized patients with severe Covid-19 pneumonia, the use of tocilizumab did not result in significantly better clinical status or lower mortality than placebo at 28 days.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Estrogen and COVID-19 symptoms: Associations in women from the COVID Symptom Study

Ricardo Costeira et al.

Summary: The study found that menopausal women had higher rates of predicted COVID-19, while users of combined oral contraceptive pills had lower rates. Hormone replacement therapy usage did not consistently show associations with COVID-19. However, caution should be taken when interpreting the results due to certain limitations in the data collection.

PLOS ONE (2021)

Add to Collection

Article Critical Care Medicine

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER) : a randomised, double-blind, parallel-group, placebo- controlled phase 3 trial

Vincent C. Marconi et al.

Summary: Although there was no significant reduction in the frequency of disease progression overall, treatment with baricitinib in addition to standard of care (including dexamethasone) had a similar safety profile to that of standard care alone, and was associated with reduced mortality in hospitalised adults with COVID-19.

LANCET RESPIRATORY MEDICINE (2021)

Add to Collection

Editorial Material Cardiac & Cardiovascular Systems

COVID-19 and the cardiovascular system

Ying-Ying Zheng et al.

NATURE REVIEWS CARDIOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

Jason D. Goldman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Remdesivir for the Treatment of Covid-19-Final Report

John H. Beigel et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Obstetrics & Gynecology

Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters

Jonathan Douxfils et al.

CONTRACEPTION (2020)

Add to Collection

Article Medicine, General & Internal

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19 A Randomized Clinical Trial

Christoph D. Spinner et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Medicine, General & Internal

Efficacy of Tocilizumab in Patients Hospitalized with Covid-19

John H. Stone et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Evidence for treatment with estradiol for women with SARS-CoV-2 infection

Ute Seeland et al.

BMC MEDICINE (2020)

Add to Collection

Correction Infectious Diseases

A minimal common outcome measure set for COVID-19 clinical research (vol 20, pg e192, 2020)

[Anonymous]

LANCET INFECTIOUS DISEASES (2020)

Add to Collection

Review Hematology

Immunoinflammatory, Thrombohaemostatic, and Cardiovascular Mechanisms in COVID-19

Selin Gencer et al.

THROMBOSIS AND HAEMOSTASIS (2020)

Add to Collection

Article Cell Biology

Effect of estetrol, a selective nuclear estrogen receptor modulator, in mouse models of arterial and venous thrombosis

Marie-Cecile Valera et al.

MOLECULAR AND CELLULAR ENDOCRINOLOGY (2018)

Add to Collection

Review Immunology

The immune System Is a natural Target for Estrogen Action: Opposing Effects of Estrogen in Two Prototypical Autoimmune Diseases

Deena Khan et al.

FRONTIERS IN IMMUNOLOGY (2016)

Add to Collection

© Peeref 2019-2024. All rights reserved.